Soyoung Kim

Soyoung Kim

Auto-generated profile, based on publicly available information

Soyoung Kim

Formerly of: Data Science, Astellas Pharma Inc., Tokyo, Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2022 in Journal of Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
MKMin Jung Kim
Min Jung Kim
JPJun Won Park
Jun Won Park
SLSun-Kyung Lee
Sun-Kyung Lee
YJYumi Jang
Yumi Jang
SKSoyoung Kim
Soyoung Kim
MPMph
Mph
Min Jung Kim, M.D., Jun Won Park, M.D., Sun-Kyung Lee, Ph.D., Yumi Jang, MPH, Soyoung Kim, MPH, Matthias Stoelzel, Ph.D., Jonathan Lumen Chua, Ph.D., Kichul Shin, M.D., Ph.D.. J Rheum Dis -0001;0:. https://doi.org/10.4078/jrd.22.0024

30 September 2025 in International Neurourology Journal
Verified
Journal Article
Open access
PDF file
KLKYU-SUNG LEE
KYU-SUNG LEE
JCJuhee Cho
Juhee Cho
DKDanbee Kang
Danbee Kang
KKKwang Jin Ko
Kwang Jin Ko
CFChee Yoong Foo
Chee Yoong Foo
SKSoyoung Kim
Soyoung Kim
Purpose: This study aimed to measure the cumulative anticholinergic burden in older outpatients in South Korea with and without newly started overactive bladder (OAB) medications, and to assess the contribution OAB treatment-related antimuscarinics have on overall anticholinergic exposure.Methods: This retrospective study utilizing the South Korean National Health Insurance Service database included patients ≥65 years old with ≥1 outpatient visit (any cause) between January 1 and June 30, 2016. The overall cohort included patients with OAB and matched patients without OAB. Outcomes were assessed over a 100-day follow-up period. Primary endpoints were 100-day cumulative anticholinergic cognitive burden score, prevalence of anticholinergic and strong anticholinergic use, and number of anticholinergics per patient. Proportion of anticholinergic cognitive burden score attributable to OAB medication was a secondary endpoint.Results: The final study cohort included 2,360 patients with OAB and 11,676 patients without OAB. Mean 100-day cumulative anticholinergic cognitive burden score was 15.2 times higher for OAB (320.1) than non-OAB (21.0). Anticholinergics were used widely for OAB patients (2,287 [96.9%] vs. 3,921 [33.6%] non-OAB patients). Prevalence of strong anticholinergic use was almost 4 times higher for OAB (2,234 patients [94.7%]) compared with non-OAB (2,817 patients [24.1%]). On average, 0.9 anticholinergics were dispensed per patient. Anticholinergic cognitive burden score attributable to OAB medications was 66.9% in the antimuscarinic-only group, 64.3% in the antimuscarinic with mirabegron group, and 0% in the mirabegron-only group.Conclusions: In patients with OAB, 100-day cumulative anticholinergic cognitive burden score was 15 times higher than in patients without OAB, due to anticholinergic medications. In this study, mirabegron did not contribute to anticholinergic burden. As there are unwanted effects associated with this burden, clinicians should consider the anticholinergic burden of each patient when using pharmacotherapy to treat OAB.